Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/ Malignancies

爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟

基本信息

批准号：
10267220
负责人：
Kathryn M. Anastos
金额：
$ 8.34万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-21 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10267220
关键词：
AIDS related cancer Address Africa Africa South of the Sahara Antibody titer measurement Bioinformatics Biological Assay Cancer Etiology Collaborations Congo Consent Data Democratic Republic of the Congo Development Disease Doctor of Philosophy Enzyme-Linked Immunosorbent Assay Epidemic Fostering Funding Funding Opportunities Genotype Geography Goals HIV HIV Infections HPV-High Risk Histopathology Human Microbiome Human Papilloma Virus-Related Malignant Neoplasm Human Papillomavirus Human Resources Human papilloma virus infection Human papillomavirus 16 Human papillomavirus 18 Immunoglobulin G Incidence Individual Infection Investigation Kaposi Sarcoma Laboratories Laboratory Research Lead Leadership Malignant Neoplasms Malignant neoplasm of anus Measurement Measures Military Hospitals Molecular Diagnostic Testing Non-Hodgkin&apos s Lymphoma Pathology Patients Persons Preventative vaccination Protocols documentation Research Research Infrastructure Research Personnel Research Project Grants Resource Sharing Resources Rwanda Sampling Serology System Teaching Hospitals Testing Time Translational Research Universities University Hospitals Viral Viral Load result Woman aged anticancer research antiretroviral therapy base cervical and anal cancer men who have sex with men microbiome analysis microbiome research microbiota molecular diagnostics molecular pathology next generation sequencing tool virus related cancer young woman

项目摘要

PROJECT SUMMARY Sub-Saharan Africa carries a disproportionate burden of HIV, with 69% of infections globally, as well as a high burden of virally induced malignancies, even before the HIV epidemic. Currently a third of all cancers in Sub- Saharan Africa are virally induced. While data from Africa are scant, evidence from other parts of the world indicates that with increasing rates of treatment with combination antiretroviral therapy for persons living with HIV (PLWH), the incidence of HIV-associated malignancies (i.e., Kaposi’s Sarcoma, non-Hodgkin’s Lymphoma) has declined dramatically. However, cancers caused by human papillomavirus (HPV), specifically invasive cervical cancer and anal cancer, have not declined and may have increased. Investigations of HPV-related malignancies are heavily dependent on laboratory testing and histopathology, which can be implemented in resource limited settings. The Rwanda/DRC/Einstein HIV-Associated HPV- Malignancies Research Center (HAMRC) proposed in this application will extend both the geographic and the scientific scope of our research and capacity-building activities. We will leverage our existing HIV research partnerships in the Democratic Republic of Congo (DRC) to include much desired research capacity to assess HPV-related cancers in PLWH. The Center proposes major studies of HPV-related malignancies through two projects: 1) evaluating the impact of HPV prophylactic vaccination in young women living with HIV; and 2) assessing HPV infection and disease in Congolese (DRC) and Rwandan men who have sex with men with and without HIV infection. In both studies we will investigate the interactions of HPV infection and disease with the local microbial flora. The Shared Resources Core addresses the goal of the HAMRC by fostering sustainable research capacity in Rwanda and the DRC to support investigation of viral-associated cancers. Thus, the specific aims of the Shared Resources Core are to provide rigorous molecular diagnostic analyses to support studies of the impact of both HAMRC projects, and to increase capacity to conduct research in HPV-related malignancies in PLWH in Rwanda and the DRC, and will specifically: 1. Replicate in the Pathology Laboratory at Université Protestante au Congo, the real-time PCR platform for hrHPV typing previously established at Rwanda Military Hospital (RMH), in the Einstein/RMH Research Laboratory. 2. Develop at the Rwanda Military Hospital (RMH), in the Einstein/RMH Research Laboratory, and in collaboration with the University of Rwanda, next generation sequencing. 3. Support further development of ELISA testing in Rwanda, at the Einstein/RMH Research Laboratory, using an assay to measure anti-HPV16 and HPV18 IgG antibody titers implementing a protocol established by the Frederick National Laboratory of Cancer Research HPV Serology Laboratory. The proposed capacity building will include personnel development of both research staff and investigators and will efficiently leverage existing research infrastructure previously developed in large part by the efforts of the proposed HARMC leadership.

项目概要撒哈拉以南非洲地区的艾滋病毒负担过重，占全球感染率的 69%，而且艾滋病毒感染率也很高病毒引起的恶性肿瘤的负担，甚至在艾滋病毒流行之前就已经存在，目前占所有癌症的三分之一。撒哈拉非洲地区是由病毒引起的，虽然来自非洲的数据很少，但来自世界其他地区的证据却很少。表明，随着患有艾滋病的人接受联合抗逆转录病毒治疗的比例不断增加 HIV (PLWH)，与 HIV 相关的恶性肿瘤（即卡波西肉瘤、非霍奇金氏肉瘤）的发病率然而，由人乳头瘤病毒（HPV）引起的癌症却急剧下降。浸润性宫颈癌和肛门癌并未下降，反而可能有所增加。 HPV 相关恶性肿瘤的调查很大程度上依赖于实验室检测和组织病理学，可以在资源有限的环境中实施卢旺达/刚果民主共和国/爱因斯坦 HIV 相关 HPV- 本申请中提议的恶性肿瘤研究中心 (HAMRC) 将扩展地理和范围我们将利用我们现有的艾滋病毒研究。刚果民主共和国 (DRC) 的合作伙伴关系包括非常需要的研究能力，以评估 PLWH 中的 HPV 相关癌症。该中心提议通过两个项目对 HPV 相关恶性肿瘤进行主要研究：1) 评估影响感染艾滋病毒的年轻女性的 HPV 预防性疫苗接种；2) 评估 HPV 感染和疾病；在这两项研究中，刚果（金）和卢旺达男性与感染或未感染艾滋病毒的男性发生性关系。我们将研究 HPV 感染和疾病与当地微生物菌群的相互作用。资源核心通过培养卢旺达和卢旺达的可持续研究能力来实现 HAMRC 的目标刚果民主共和国支持病毒相关癌症的研究因此，共享的具体目标。核心资源将提供严格的分子诊断分析，以支持对两者影响的研究 HAMRC 项目，并提高在 PLWH 中开展 HPV 相关恶性肿瘤研究的能力卢旺达和刚果民主共和国，并将具体： 1. 在刚果新教大学病理实验室实时 PCR 平台上复制用于先前在卢旺达军事医院 (RMH) 建立的 hrHPV 分型，位于 Einstein/RMH 研究实验室。 2. 在卢旺达军事医院 (RMH)、爱因斯坦/RMH 研究实验室和与卢旺达大学合作，进行下一代测序。 3. 支持卢旺达爱因斯坦/RMH 研究实验室进一步开发 ELISA 检测，使用测定法来测量实施方案的抗 HPV16 和 HPV18 IgG 抗体滴度由弗雷德里克国家癌症研究实验室建立的HPV血清学实验室。拟议的能力建设将包括研究人员和调查人员的人员发展以及将有效地利用现有的研究基础设施，这些基础设施以前在很大程度上是由建议 HARMC 领导。